Strategic Wealth Partners Ltd. Invests $255,000 in Exact Sciences Co. (NASDAQ:EXAS)

Strategic Wealth Partners Ltd. bought a new position in Exact Sciences Co. (NASDAQ:EXAS) in the third quarter, HoldingsChannel.com reports. The fund bought 3,750 shares of the medical research company’s stock, valued at approximately $255,000.

A number of other hedge funds have also modified their holdings of EXAS. Harbert Fund Advisors Inc. acquired a new stake in Exact Sciences during the 4th quarter valued at $507,000. Spouting Rock Asset Management LLC boosted its position in shares of Exact Sciences by 5.2% in the 4th quarter. Spouting Rock Asset Management LLC now owns 11,454 shares of the medical research company’s stock worth $847,000 after purchasing an additional 567 shares during the last quarter. Able Wealth Management LLC bought a new position in shares of Exact Sciences in the 4th quarter worth $45,000. Integrated Advisors Network LLC boosted its position in shares of Exact Sciences by 24.6% in the 4th quarter. Integrated Advisors Network LLC now owns 5,397 shares of the medical research company’s stock worth $399,000 after purchasing an additional 1,065 shares during the last quarter. Finally, Syon Capital LLC bought a new position in shares of Exact Sciences in the 4th quarter worth $215,000. 88.82% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Exact Sciences news, EVP Brian Baranick sold 929 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the transaction, the executive vice president now owns 13,687 shares of the company’s stock, valued at $958,090. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.36% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Wells Fargo & Company started coverage on Exact Sciences in a report on Tuesday, August 27th. They set an “overweight” rating and a $75.00 target price on the stock. Evercore ISI boosted their price target on Exact Sciences from $72.00 to $80.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Raymond James restated a “market perform” rating on shares of Exact Sciences in a report on Thursday, September 26th. Piper Sandler boosted their price target on Exact Sciences from $75.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday, September 12th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $75.00 price target on shares of Exact Sciences in a report on Friday, September 13th. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $78.38.

Exact Sciences Price Performance

Shares of NASDAQ EXAS opened at $69.34 on Friday. The business’s 50 day moving average price is $62.89 and its two-hundred day moving average price is $56.63. The company has a market cap of $12.80 billion, a PE ratio of -52.53 and a beta of 1.27. The company has a quick ratio of 1.98, a current ratio of 2.17 and a debt-to-equity ratio of 0.73. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.28. The firm had revenue of $699.26 million for the quarter, compared to the consensus estimate of $690.02 million. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The business’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.45) earnings per share. On average, analysts predict that Exact Sciences Co. will post -0.87 EPS for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.